[TaiCang Biotechnology] The Company's Q1 2026 Consolidated Financial Report Approved by the Board of Directors
NQ Score
0/100
N1 Content Completeness
4
AI Summary (NQ-processed)
TaiCang Biotechnology announced that its consolidated financial report for the first quarter of 2026 (January 1 to March 31) has been approved by the board of directors. The accumulated operating revenue for the period was NT$308,435 thousand, with a pre-tax net loss of NT$141,836 thousand and basic EPS of (NT$0.47). Both the board of directors and the audit committee approved the report on May 12, 2026.